Results 31 to 40 of about 178 (95)

CLINICAL AND ECONOMIC ANALYSIS OF GENETICALLY ENGINEERED BIOLOGICS CONSUMPTION BY PATIENTS WITH COVID-19

Фармация и фармакология (Пятигорск), 2022
The aim of the article is a comparative clinical and economic assessment of genetically engineered monoclonal antibodies against interleukins in infectious diseases facilities in Volgograd region, reassigned to treat COVID-19 patients.Materials and ...
V. I. Petrov, N. Yu. Ryazanova, A. V. Ponomareva, O. V. Shatalova, Ya. V. Levina   +4 more
doaj   +1 more source

FRI0114 EFFICACY OF LEVILIMAB, NOVEL MONOCLONAL ANTI-IL-6 RECEPTOR ANTIBODY, IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: 1-YEAR RESULTS OF PHASE 2 AURORA STUDY [PDF]

Annals of the Rheumatic Diseases, 2020
Background: Previously, 12-week results of phase 2 clinical study of levilimab (LVL) in patients with active rheumatoid arthritis (RA) have been reported1. The study has met the primary endpoint at W12 confirming that treatment with LVL 162 mg SC + methotrexate (MTX) either QW or Q2W is superior to MTX alone in patients with RA and inadequate response
V. Mazurov, E. Zotkin, E. Ilivanova, T. Kropotina, T. Plaksina, O. Nesmeyanova, N. Soroka, A. Kundzer, A. Lutskii, E. Dokukina, A. Eremeeva, A. Zinkina-Orihan   +11 more
openaire   +1 more source

Efficacy of levilimab for prevention of hospitalizations in the outpatients with COVID-19

Clinical pharmacology and therapy
To evaluate the efficacy of early administration of levilimab for prevention of hospitalizations in outpatients with COVID-19.
E.V. Shikh, V.N. Drozdov, Zh.M. Sizova, T.N. Nizhenko   +3 more
openaire   +1 more source

Risk of secondary bacterial infections during treatment with anti-inflammatory genetically engineered biological drugs in COVID-19 patients

Фармация и фармакология (Пятигорск)
The aim of the work was to identify the presence and strength of association between the use of anti-inflammatory genetically engineered biological drugs and the development of secondary bacterial infections in COVID-19 patients.Materials and methods. We
V. I. Petrov, A. Yu. Ryazanova, N. S. Tokareva   +2 more
doaj   +1 more source

Effectiveness and safety of olokizumab and levilimab in patients with COVID-19 in 2022: a cohort study

Journal of Volgograd State Medical University
A single-center observational cohort study of the use of levilimab and olokizumab in patients with COVID-19 was conducted. Purpose was to evaluate the effectiveness and safety of olokizumab and levilimab in the infectious diseases hospital of the Volgograd region in 2022.
Vladimir I. Petrov, Anastasia Yu. Ryazanova, Natalya S. Tokareva   +2 more
openaire   +1 more source

The Effect of Potentially Hepatotoxic Medicinal Products on Alanine Transaminase Levels in COVID-19 Patients: A Case–Control Study

Безопасность и риск фармакотерапии
INTRODUCTION. Elevated liver enzyme levels are common in patients with COVID-19. Personalised prescribing to reduce the risk of hepatotoxicity requires studying the role of pharmacotherapy in the development of liver dysfunction in COVID-19 patients.AIM.
V. I. Petrov, A. Yu. Ryazanova, N. S. Tokareva   +2 more
doaj   +1 more source

Quantitative Signal Detection for COVID-19 Medicinal Products Based on Retrospective Analysis of Spontaneous Reports from the Russian Pharmacovigilance Database

Безопасность и риск фармакотерапии
SCIENTIFIC RELEVANCE. The pandemic of novel coronavirus infection (COVID-19) led to a drastic increase in the use of medicinal products of various therapeutic groups and increased spontaneous reporting of adverse drug reactions (ADRs).
S. A. Mishinova, A. S. Kolbin, Yu. S. Polushin, E. V. Verbitskaya   +3 more
doaj   +1 more source

Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6

Научно-практическая ревматология
Giant cell arteritis (GCA) and polymyalgia rheumatica (RPM) are immune-mediated rheumatic disease (IMRDs), which typically develop in people over 50 years of age.
Evgeny L. Nasonov, Azamat M. Satybaldyev, Elvira N. Otteva, Tatiana V. Beketova, Andrey A. Baranov   +4 more
doaj   +1 more source

Levilimab [PDF]

Reactions Weekly, 2021
openaire   +1 more source

The effect of levilimab on the clinical presentations and changes in inflammatory biomarkers in outpatients with mild to moderate COVID-19

Meditsinskiy sovet = Medical Council
Introduction. It is now well known that a proportion of patients with COVID-19 develop a pathological systemic inflammatory response with complications resulting in multiple organ failure. The severity and prognosis of the disease, as well as the effectiveness of the treatment provided should be assessed as early as possible. For this purpose, a number
T. N. Nizhenko, E. V. Shikh, Zh. M. Sizova, V. N. Drozdov, N. I. Lapidus, A. E. Pakhomova   +5 more
openaire   +1 more source